ID
38934
Beskrivning
Study ID: 111364 Clinical Study ID: 111364 Study Title: A 28-Day, Polysomnographic and subjective assessment of Vestipitant (15mg/day) for the treatment of Primary Insomnia in adult Outpatients Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992160 Clinicaltrials.gov Links: https://clinicaltrials.gov/ct2/show/NCT00992160 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Vestipitant, Placebo Trade Name: N/A Study Indication: Primary Insomnia, Sleep Disorders This phase II, placebo-controlled, double-blind trial studies the polysomnographic and subjective effect of the neurokinin (NK1) antagonist vestipitant (15mg/day at bedtime) for the treatment of primary insomnia in adult outpatients over a period of four weeks. The study consists of a clinical Screening Visit (Visit 1), up to 21 days before investigational product/placebo initiation, two screening polysomnographies (Visits 2 and 3), followed by a placebo run-in until Visit 4, at which the subject is randomized to vestipitant or placebo, taken every night for 28 days. On Day 1 and 2 (Visits 4 and 5), polysomnographies are performed. Visit 6 is a safety visit on Day 15. On Day 27 and 28, Visits 7 and 8 are performed, which again include polysomnography studies. Subjects then undergo a 7 to 10 day placebo run-out period and have Day 7 and Day 14 Follow-Up Visit (Visits 9 and 10). The purpose of this form is to record whether consent for PGx Pharmacogenetic Research has been withdrawn, and whether the sample was requested to be destroyed.
Länk
https://clinicaltrials.gov/ct2/show/NCT00992160
Nyckelord
Versioner (1)
- 2019-11-14 2019-11-14 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
14 november 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Polysomnographic Assessment of Vestipitant for the Treatment of Primary Insomnia NCT00992160
Pharmacogenetic Research Consent Withdrawal
- StudyEvent: ODM
Beskrivning
Withdrawal of consent for PGx (DNA) sample destruction
Alias
- UMLS CUI-1
- C1707492
- UMLS CUI-2
- C0031325
- UMLS CUI-3
- C0035168
- UMLS CUI-4
- C1948029
- UMLS CUI-5
- C0444245
Beskrivning
If yes, record date
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1707492
- UMLS CUI [1,2]
- C0031325
- UMLS CUI [1,3]
- C0035168
Beskrivning
If applicable
Datatyp
date
Alias
- UMLS CUI [1,1]
- C1707492
- UMLS CUI [1,2]
- C0031325
- UMLS CUI [1,3]
- C0035168
- UMLS CUI [1,4]
- C0011008
Beskrivning
If yes, record reason below
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1272683
- UMLS CUI [1,2]
- C1948029
- UMLS CUI [1,3]
- C0444245
Beskrivning
If other reason, specify below
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0566251
- UMLS CUI [1,2]
- C1272683
- UMLS CUI [1,3]
- C1948029
- UMLS CUI [1,4]
- C0444245
Beskrivning
if applicable
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1521902
- UMLS CUI [1,2]
- C3840932
- UMLS CUI [1,3]
- C1272683
- UMLS CUI [1,4]
- C1948029
- UMLS CUI [1,5]
- C0444245
Similar models
Pharmacogenetic Research Consent Withdrawal
- StudyEvent: ODM
C2985720 (UMLS CUI [2])
C0031325 (UMLS CUI-2)
C0035168 (UMLS CUI-3)
C1948029 (UMLS CUI-4)
C0444245 (UMLS CUI-5)
C0031325 (UMLS CUI [1,2])
C0035168 (UMLS CUI [1,3])
C0031325 (UMLS CUI [1,2])
C0035168 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C1948029 (UMLS CUI [1,2])
C0444245 (UMLS CUI [1,3])
C1272683 (UMLS CUI [1,2])
C1948029 (UMLS CUI [1,3])
C0444245 (UMLS CUI [1,4])
C3840932 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C1948029 (UMLS CUI [1,4])
C0444245 (UMLS CUI [1,5])